Chemomab Supplement Discloses $1.1M Scipher ATM Purchase and Updated Merger Exchange Ratio
CMMB sits 46% above its 52-week low of $0.92.
Summary
Chemomab's merger proxy supplement discloses that Scipher bought 932,203 ADSs at $1.18 for about $1.1 million under the existing ATM program, and updates the expected exchange ratio to roughly 0.168 Chemomab Parent shares per ADS ahead of the December 4 vote.
Key Events · M&A and Partnerships · CMMB
-
Scipher Buys $1.1M of ADSs Pre-Vote
On November 3, 2026, Scipher purchased 932,203 ADSs (74,576,240 Chemomab Israel Shares) at $1.18 per ADS for about $1.1 million gross and roughly $1,042,000 net after the LifeSci Capital commission, under the ATM program established July 25, 2025.
-
Committed Merger Financing, Not Open-Market Demand
Section 5.6 of the Merger Agreement required the purchase, under which Scipher agreed to provide up to $1.1 million if Chemomab needed financing before closing; the shares were issued after the October 29 record date and cannot be voted at the December 4 meeting.
-
Additional Notes Carry a Forfeiture Clause
Scipher issued Additional Notes of up to $1.1 million under Amendment No. 3 to the 2026 CNPA, with $858,612 issued from October 29 to November 3, 2026 and about $241,387 still available; 2026 Note holders that fail to fund by November 28, 2026 have their notes subordinated and cancelled for no consideration.
-
Exchange Ratio Updated to 0.168 Per ADS
Based on 8,988,503 ADSs and options for 514,072 ADSs outstanding as of November 6, 2026, the illustrative Domestication Exchange Ratio is about 0.0021, or 0.168 Chemomab Parent shares per ADS, with the final ratio still subject to closing-date valuations and share counts.
Analysis · CMMB · Life Sciences
Ahead of the December 4 shareholder vote, this supplement to the October 30 merger proxy reveals that merger counterparty Scipher bought 932,203 Chemomab ADSs at $1.18 each for about $1.1 million, funding Chemomab's runway. Because the purchase was required under Section 5.6 of the Merger Agreement, it represents committed merger financing rather than open-market demand, and the shares carry no vote since they were issued after the October 29 record date. The same filing quantifies the mechanics shareholders will vote on: an updated Domestication Exchange Ratio of about 0.168 Chemomab Parent shares per ADS, and post-closing ownership of roughly 56.7% Scipher, 26.7% Chemomab and 16.6% PIPE investors assuming the $30 million minimum PIPE. While the $1.18 ADS price compares with today's $1.345 quote, the deal was struck on November 3 and the filing does not characterize it as a premium or discount.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.92 to $2.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.